Clinical trial NCT01625520: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Official title: Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Medullary Thyroid Cancer
Keywords: Progressive metastatic
postoperative persistent
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2012-06-21
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.

Detailed description: Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from thyroid C cells. Neuroendocrine tumors have been demonstrated to express somatostatin receptors as well as mTOR pathway. The somatostatin analogues now available (octreotide and lanreotide) act preferentially through the somatostatin receptor subtype 2 (sst2). In MTC, these compounds have been reported to exert anti-secretive effects on calcitonin but no anti-proliferative effects.SOM230 (pasireotide) is a new somatostatin analogue showing a peculiar binding profile with high affinity for sst1, sst2, sst3, sst5. Preliminary data show SOM230 to be effective in a phase II study on patients with metastatic carcinoid. RAD001 (everolimus) is a novel agent that interacts with mTOR. It was demonstrated to inhibit tumor growth in neuroendocrine tumor cell lines. Some clinical trials have explored the efficacy of a combined therapy with RAD001 plus octreotide in patients with digestive neuroendocrine tumors, highlighting encouraging results in term of tumor control.In particular, octreotide and RAD001 seem to show a synergistic activity in inhibiting neuroendocrine tumor proliferation.

Eligibility criteria: Inclusion Criteria:

* Patients with progressive metastatic or postoperative persistent medullary thyroid cancer who have histopathologically confirmed disease and measurable tumor lesions. (Postoperative persistent after surgical removal is characterized by increased levels of calcitonin with or without radiological detectable tumour relapse or metastases.)
* Patients with evidence of biochemical progression of disease, as expressed by progressive increase of serum calcitonin levels, assessed once a month for at least three months before study entry, according to RECIST definitions (elevation of the markers for at least 25 %).
* Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
* Adequate organ function - Karnofsky-Index performance status \>60%
* Life expectancy \> 6 months
* Age \> 18 years
* Women of childbearing potential must have a negative serum pregnancy test within 14 days of randomization and a urine pregnancy test 48 hours prior to the administration of the first study treatment.
* Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary.
* Signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial prior to enrolment.

Exclusion Criteria:

* Unstable systemic diseases including uncontrolled hypertension, active uncontrolled infections, psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
* Known hypersensitivity to somatostatin analogues.
* Pregnant or breast-feeding patients
* Sign of recurrence of prior or concomitant malignancies (within the last 3 years or requiring active treatment) other than MTC; with the exception of previous basal cell skin cancer, previous cervical carcinoma in situ
* Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus)
* Participation in a clinical trial to test an investigational drug within 4 weeks prior to visit 1.
* Any of severe and/or uncontrolled medical conditions:
* Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment,
* QT related exclusion criteria
* Previous treatments with chemotherapy, loco regional therapy (eg, chemoembolization) or interferon are permitted providing that toxicity has resolved to \< Grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.

Primary outcomes:
measure: Efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer
timeFrame: From date of start therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary outcomes:
measure: Efficacy of SOM230 in combination with RAD001 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.
timeFrame: From date of start therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
measure: Biochemical response
timeFrame: From date of start therapy, 1 month, 2 month, 3 month, 6 month time point evaluation, up to 6 months.
measure: Objective tumor response
timeFrame: From date of start therapy, 3 month, 6 month time point evaluation, up to 6 months.
measure: Overall survival
timeFrame: From date of start therapy to the end of the study or death from any cause, whichever came first, up to 6 months.
measure: Time to response
timeFrame: From date of start therapy, 3 month, 6 month time point evaluation, up to 6 months.
measure: Duration of response
timeFrame: From time of response to time of tumor progression or death from any cause, whichever came first.
measure: Safety
timeFrame: From date of start therapy until the end of the study, every 30 days, up to 6 months.
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples
Study officials:
affiliation: "Federico II" University of Naples, Italy
name: Annamaria Colao
role: PRINCIPAL_INVESTIGATOR
References:
citation: Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23.